Quick Answer
Amneal Pharmaceuticals, Inc. reported Net Income Loss of $72.06 million for the year ending 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +161.6% in Net Income Loss from 2024 to 2025.
- This data is from Amneal Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $72.06 million | Fiscal year 2024: -$116.89 million | Fiscal year 2023: -$83.99 million | Fiscal year 2022: -$270.58 million | Fiscal year 2021: $13.16 million | Fiscal year 2020: $67.79 million | Fiscal year 2019: -$603.57 million | Fiscal year 2018: -$19.74 million | Fiscal year 2017: $0.00 | Fiscal year 2016: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: